Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Herbst RS, et al. Among authors: eckhardt sg. J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458040 Clinical Trial.
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. Camidge DR, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Feb 15;16(4):1256-63. doi: 10.1158/1078-0432.CCR-09-1267. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145186 Clinical Trial.
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. Hong DS, et al. Among authors: eckhardt sg. Clin Cancer Res. 2012 Aug 1;18(15):4173-82. doi: 10.1158/1078-0432.CCR-12-0714. Epub 2012 Jun 12. Clin Cancer Res. 2012. PMID: 22693357 Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L. Gordon MS, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068101 Clinical Trial.
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. Kurzrock R, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Apr 15;16(8):2458-65. doi: 10.1158/1078-0432.CCR-09-3220. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371689 Clinical Trial.
Angiogenesis inhibitors in clinical development for lung cancer.
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Herbst RS, et al. Among authors: eckhardt sg. Semin Oncol. 2002 Feb;29(1 Suppl 4):66-77. doi: 10.1053/sonc.2002.31527. Semin Oncol. 2002. PMID: 11894016 Review.
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK. Villalona-Calero MA, et al. Among authors: eckhardt sg. J Clin Oncol. 1999 Jun;17(6):1915-25. doi: 10.1200/JCO.1999.17.6.1915. J Clin Oncol. 1999. PMID: 10561233 Clinical Trial.
360 results